I think the eGFR broker talk tada is referring to was probably talk based in fact around pooled Sustain and Assure results which showed that the patients in those trials on drug with mild to moderate renal failure had improved eGFR of 3.4% while those in the control groups saw a decline in eGFR of -5.9%.  This information has been available for quite some time and is very easy to find.